IS5605A - Aðferð fyrir samruna á eyðniveiru (HIV) próteasa lötum - Google Patents

Aðferð fyrir samruna á eyðniveiru (HIV) próteasa lötum

Info

Publication number
IS5605A
IS5605A IS5605A IS5605A IS5605A IS 5605 A IS5605 A IS 5605A IS 5605 A IS5605 A IS 5605A IS 5605 A IS5605 A IS 5605A IS 5605 A IS5605 A IS 5605A
Authority
IS
Iceland
Prior art keywords
lysis
protease inhibitors
hiv virus
virus protease
hiv
Prior art date
Application number
IS5605A
Other languages
English (en)
Other versions
IS2273B (is
Inventor
Al-Farhan Emile
D. Deininger David
Dennis Tung Roger
Mcghie Stephen
Rout Stephen
Singh Hardev
O'callaghan John
Stuart Robertson Mark
Rodgers Keith
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5605A publication Critical patent/IS5605A/is
Publication of IS2273B publication Critical patent/IS2273B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IS5605A 1998-03-20 2000-08-29 Aðferð fyrir nýsmíðina á HIV próteasa lötum IS2273B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805898.5A GB9805898D0 (en) 1998-03-20 1998-03-20 Process for the sythesis of hiv protease inhibitors
PCT/GB1999/000852 WO1999048885A1 (en) 1998-03-20 1999-03-18 Process for the synthesis of hiv protease inhibitors

Publications (2)

Publication Number Publication Date
IS5605A true IS5605A (is) 2000-08-29
IS2273B IS2273B (is) 2007-07-15

Family

ID=10828884

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5605A IS2273B (is) 1998-03-20 2000-08-29 Aðferð fyrir nýsmíðina á HIV próteasa lötum

Country Status (31)

Country Link
US (1) US6281367B1 (is)
EP (1) EP1066276B1 (is)
JP (1) JP3363439B2 (is)
KR (1) KR100555278B1 (is)
CN (1) CN1308319C (is)
AP (1) AP1226A (is)
AT (1) ATE242772T1 (is)
AU (1) AU751534B2 (is)
BR (1) BR9908970A (is)
CA (1) CA2324217C (is)
CZ (1) CZ299193B6 (is)
DE (1) DE69908761T2 (is)
DK (1) DK1066276T3 (is)
EA (1) EA003022B1 (is)
EE (1) EE04750B1 (is)
ES (1) ES2203090T3 (is)
GB (1) GB9805898D0 (is)
HR (1) HRP20000609B1 (is)
HU (1) HUP0105439A3 (is)
ID (1) ID26587A (is)
IL (1) IL138127A (is)
IS (1) IS2273B (is)
NO (1) NO317648B1 (is)
NZ (1) NZ506563A (is)
PL (1) PL201810B1 (is)
PT (1) PT1066276E (is)
RS (1) RS49954B (is)
SK (1) SK283939B6 (is)
TR (1) TR200002698T2 (is)
WO (1) WO1999048885A1 (is)
ZA (1) ZA200004482B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0810209T3 (da) 1992-08-25 2002-08-12 Monsanto Co Alpha - and beta-aminosyre-hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
WO2001046120A1 (en) * 1999-12-23 2001-06-28 Aerojet Fine Chemicals Llc Improved preparation of 2s,3s-n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
EP2767539B1 (en) 2002-05-16 2017-07-12 Janssen Sciences Ireland UC Pseudopolymorphic forms of a HIV protease inhibitor
HRP20090488T1 (hr) * 2003-12-23 2009-10-31 Tibotec Pharmaceuticals Ltd. Postupak za pripravu (3r,3as,6ar)-heksahidrofuro[2,3-b]furan-3-il(1s,23)-3-[[(4-aminofenil)sulfonil](izobutil)amino]-1-benzil-2-hidroksipropilkarbamata
US7772411B2 (en) 2003-12-23 2010-08-10 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
CN111233794A (zh) * 2020-03-27 2020-06-05 江巨东 一种安普那韦的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
DK0810209T3 (da) * 1992-08-25 2002-08-12 Monsanto Co Alpha - and beta-aminosyre-hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease

Also Published As

Publication number Publication date
JP3363439B2 (ja) 2003-01-08
ID26587A (id) 2001-01-18
IL138127A (en) 2003-10-31
DK1066276T3 (da) 2003-10-06
WO1999048885A1 (en) 1999-09-30
CZ20003457A3 (cs) 2001-04-11
KR20010042022A (ko) 2001-05-25
IS2273B (is) 2007-07-15
BR9908970A (pt) 2000-11-28
US6281367B1 (en) 2001-08-28
HUP0105439A3 (en) 2002-08-28
IL138127A0 (en) 2001-10-31
ATE242772T1 (de) 2003-06-15
AP2000001911A0 (en) 2000-09-30
DE69908761D1 (de) 2003-07-17
HUP0105439A2 (en) 2002-06-29
HRP20000609B1 (en) 2006-05-31
EP1066276A1 (en) 2001-01-10
SK283939B6 (sk) 2004-05-04
ZA200004482B (en) 2001-11-28
AU2947599A (en) 1999-10-18
AU751534B2 (en) 2002-08-22
NZ506563A (en) 2003-05-30
NO20004664L (no) 2000-09-19
EA003022B1 (ru) 2002-12-26
HRP20000609A2 (en) 2001-04-30
PL201810B1 (pl) 2009-05-29
EE04750B1 (et) 2006-12-15
CA2324217A1 (en) 1999-09-30
AP1226A (en) 2003-11-21
SK13732000A3 (sk) 2001-08-06
EA200000859A1 (ru) 2001-04-23
NO317648B1 (no) 2004-11-29
CN1293668A (zh) 2001-05-02
EP1066276B1 (en) 2003-06-11
CA2324217C (en) 2008-02-19
JP2002507609A (ja) 2002-03-12
HK1032047A1 (en) 2001-07-06
TR200002698T2 (tr) 2000-12-21
PL342602A1 (en) 2001-06-18
NO20004664D0 (no) 2000-09-19
EE200000568A (et) 2002-02-15
PT1066276E (pt) 2003-10-31
DE69908761T2 (de) 2004-02-19
GB9805898D0 (en) 1998-05-13
CZ299193B6 (cs) 2008-05-14
ES2203090T3 (es) 2004-04-01
YU55900A (sh) 2003-02-28
CN1308319C (zh) 2007-04-04
RS49954B (sr) 2008-09-29
KR100555278B1 (ko) 2006-03-03

Similar Documents

Publication Publication Date Title
NO991832D0 (no) Inhibitorer for serin-proteaser, spesielt hepatitt - C - virus NS3-protease
EE200000798A (et) HIV proteaasi inhibiitori bisulfaatsool
NO20012980D0 (no) Proteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
NO995316D0 (no) Serinproteaseinhibitorer
NO995660D0 (no) Fremgangsmåte ved kommunikasjon og anordning for samme
PT1086076E (pt) Inibidores de sulfonamida de aspartil protease
NO20004696L (no) Kinoloner som serinproteaseinhibitorer
NO995434D0 (no) Proteaseinhibitorer
NO20010674L (no) Forbedret fremgangsmåte for to-bölgefelts-forsterkning
IS5605A (is) Aðferð fyrir samruna á eyðniveiru (HIV) próteasa lötum
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
FI960206L (fi) Menetelmä HIV-proteaasi-inhibiittoreiden valmistamiseksi
DZ2815A1 (fr) Inhibiteurs de protéase.
IS5018A (is) Aðferð til alkýeringar á hindruðum súlfónamíðum
DK1361216T3 (da) Fremgangsmåde til fremstilling af en HIV-proteaseinhibitor
EE04114B1 (et) HIV-proteaasi inhibiitorid
AU2002350322A1 (en) Inhibitors of hepatitis c virus protease
NO20054575L (no) Fremgangsmate ved kommunikasjon og anordning for samme
FI991301A0 (fi) Menetelmä elohopean talteenottamiseksi
MA26429A1 (fr) Inhibiteurs de protease